Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
We created the first FDA-cleared device supports concurrent reading, allowing for faster reading with proven, superior, automatic nodule detection.
Our four FDA-cleared applications are designed to improve reading efficiency and accuracy across the hospital enterprise without requiring additional hardware.
Riverain’s deep learning AI technology is FDA cleared, field tested, and clinically proven to provide real results in radiology.
Riverain Technologies advanced AI imaging software is in use by leading healthcare organizations around the world.
Peer reviews, reference accounts, and independent studies confirm that ClearRead technology is positively impacting the field of radiology.
Riverain Technologies – a US-based developer of AI-powered software that analyzes chest X-rays and CT images – announced Wednesday that the Therapeutic Goods of Australia (TGA) cleared more of the company’s AI solutions for sale and distribution in Australia, including ClearRead CT and ClearRead Xray Confirm (Enhanced). These solutions are joining ClearRead Xray Bone Suppress and ClearRead Xray Compare that have been TGA-cleared since 2009.
ClearRead solutions significantly improve a clinician’s ability to accurately and efficiently detect disease, suppressing vessels in thoracic CT and bone structures in chest X-ray images for earlier, more efficient detection of lung abnormalities. Powered by the most advanced machine learning and modeling methods available to the medical imaging market, the patented, FDA-cleared, CE marked, and now TGA-cleared software tools are deployable in the clinic or the Cloud:
ClearRead solutions are in use globally, including Germany, Japan, Australia, Canada, and many institutions in the United States.